Nuo Therapeutics, Inc. AURX
We take great care to ensure that the data presented and summarized in this overview for Nuo Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AURX
View allLatest Institutional Activity in AURX
Top Purchases
Top Sells
About AURX
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
Insider Transactions at AURX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Nov 15
2024
|
Scott M. Pittman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
217,709
+1.34%
|
$0
$0.43 P/Share
|
|
Sep 18
2024
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
125,000
+1.08%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+2.54%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+2.5%
|
$0
$0.75 P/Share
|
|
May 20
2024
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+0.88%
|
$0
$0.75 P/Share
|
|
Dec 19
2023
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.32%
|
$0
$0.5 P/Share
|
|
Dec 19
2023
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+10.63%
|
$0
$0.5 P/Share
|
|
Dec 19
2023
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+3.38%
|
$0
$0.5 P/Share
|
|
Aug 01
2023
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
62,500
+0.56%
|
$125,000
$2.0 P/Share
|
|
Aug 01
2023
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+2.2%
|
$200,000
$2.0 P/Share
|
|
Aug 01
2023
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+4.34%
|
$50,000
$2.0 P/Share
|
|
Nov 09
2022
|
David Emerson Jorden CEO/CFO |
SELL
Open market or private sale
|
Direct |
162,500
-0.87%
|
$162,500
$1.5 P/Share
|
|
Apr 29
2022
|
Charles E Sheedy > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
804,868
+6.82%
|
$804,868
$1.0 P/Share
|
|
Apr 29
2022
|
Scott M. Pittman Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+2.25%
|
$100,000
$1.0 P/Share
|
|
Apr 29
2022
|
Peter Clausen CSO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+4.54%
|
$25,000
$1.0 P/Share
|
|
Apr 29
2022
|
David Emerson Jorden CEO/CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,532
+0.49%
|
$10,532
$1.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 150K shares |
|---|---|
| Exercise of conversion of derivative security | 218K shares |
| Open market or private purchase | 225K shares |